Comparing the current results to its competitors, Oncolytics Biotech Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 15.88 %, recorded in the same quarter.
Oncolytics Biotech Inc , slower than the average decrease reported by the company's competitors of -33.33 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -33.33 %
Oncolytics Biotech Inc 's Comment on Competition and Industry Peers
The company is not currently aware of competing intellectual property related to its pelareorep project but recognizes potential future challenges. Competitors include large biopharmaceutical companies with greater financial, manufacturing, marketing, and drug development resources, as well as smaller or early-stage companies, particularly those with collaborations involving large companies or research institutions. Competitors operate within treatment categories such as traditional cancer therapies (chemotherapy, surgery, radiation therapy, targeted therapies), approved and clinical trial immunotherapy antibodies, approved and clinical trial oncolytic virus-based immunotherapies, cancer vaccines—including personalized and tumor neo-antigen targeting vaccines—and cell-based therapies (CAR-T, T cell receptor-based, NK cell therapies). Pelareorep will compete with drugs targeting cancer through various mechanisms and must demonstrate improved clinical efficacy and/or safety. The company also competes in recruiting personnel, establishing clinical trial sites, enrolling patients, and acquiring complementary technologies. Pelareorep is expected to be used in combination with other cancer treatments, including checkpoint inhibitors, surgery, chemotherapy, radiation therapy, and other biological therapies.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Hutchmed China Limited operates on a vertically integrated platform, focusing on the discovery, development, and commercialization of targeted therapeutics for oncology and immunological diseases. The company employs a comprehensive business model that encompasses research and development, manufacturing, marketing, and sales in order to deliver innovative drugs to patients. By leveraging its internal capabilities and strategic partnerships, Hutchmed China aims to transform the treatment landscape and improve the lives of patients in China and around the world.
Sources:
Oncolytics Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oncolytics Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
